[3][7] Following a decision of the Russian Government, the association was created "to provide for the country's needs for preventive, diagnostic and therapeutic immunobiological preparations".

[10] In 2011, the company received the first samples of bacteriophage preparation against the pathogen Acinetobacter, which is the causative agent of a large number of hospital-acquired (nosocomial) infections and is resistant to antibiotics.

[21] In March 2014 the company announced the development of a new generation of vaccines against tick-borne encephalitis based on continuous cell lines.

[22] In April 2014, Microgen announced the launch of clinical trials of the new combined penta-vaccine aDTB-HepB-Hib (diphtheria, pertussis, tetanus, hepatitis B, and infections caused by Haemophilus influenzae).

[3] Its major production sites are located in Stavropol, Irkutsk, Nizhny Novgorod ("ImBio"), Moscow, Tomsk ("Virion"), Perm ("Biomed") and Ufa ("Immunopreparat").

In 2021, the Rostec State Corporation transferred 100% of the shares of NPO Microgen to the Nacimbio holding[42] The company produces more than 70% of the total Russian immunobiological products, including two of the four vaccines against A/H1N1.

[45] Microgen produces a range of over 120 immunobiological products: vaccines, sera, specific and polyvalent immunoglobulins, nutrient medium, allergens, probiotics etc.

[21][56][57] Its medical drugs and products are exported to Kazakhstan, Ukraine,[58][59] Belarus,[60] Uzbekistan, Azerbaijan, Armenia, Georgia, Mexico, Mongolia, Vietnam and India.

[4][9][10][12][63][64] Microgen is involved in several international research projects, including the WHO program to combat smallpox, measles, rubella, tuberculosis, avian influenza, etc.

[2] In 2014, Russia's VTB Bank extended a credit line for the FSUE SPA Microgen to the amount of RUB 2 bln., for a period of 3 years.